Download PDF Open All

Rocuronium

high alert medication

Nondepolarizing neuromuscular blocking agent

CCP: Areflexia for rapid sequence intubation

 

Known hypersensitivity or allergy to rocuronium bromide or any component of the formulation

 

CCP: Areflexia for rapid sequence intubation

  • 0.6-1.2 mg/kg IV
    • Based on actual body weight

Follow weight-based dosing

CCP: Areflexia for rapid sequence intubation

  • For patients between 3 months and 14 years of age
  • 0.6 mg/kg IV  

Produces skeletal muscle relaxation by inhibiting the activity of acetylcholine at the neuromuscular junction.  Does not alter the resting electrical potential of the motor end plate, or cause muscular contraction. 

Intravenous:

  • Onset: 1-1.5 minutes for clinically sufficient neuromuscular blockade
  • Peak: 3-4 minutes
  • Duration: 
    • Doses of 0.6 mg/kg: 30 minutes
    • Doses of 1.2 mg/kg: 67 minutes
    • Doses of 2 mg/kg: 110 minutes

Skeletal muscle weakness

warning

Administration of rocuronium produces paralysis and compromises respiratory function.  Rocuronium must only be used by paramedics trained and experienced in its use, and where effective oxygenation and ventilation can be maintained. 

Succinylcholine: administer rocuronium only after the patient has recovered from succinylcholine-induced neuromuscular blockade

Magnesium sulfate: increases duration of neuromuscular blockade from rocuronium

 

Are you sure you want to sign out?

Sign Out Cancel

loading